New Zealand markets closed

Agenus Inc. (AGEN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
16.00-0.92 (-5.44%)
At close: 04:00PM EDT
16.00 0.00 (0.00%)
After hours: 07:51PM EDT

Agenus Inc.

3 Forbes Road
Lexington, MA 02421-7305
United States
781 674 4400
https://www.agenusbio.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees389

Key executives

NameTitlePayExercisedYear born
Dr. Garo H. Armen Ph.D.Founder, Executive Chairman & CEO1.34MN/A1953
Ms. Christine M. KlaskinVP of Finance, Principal Financial Officer & Principal Accounting Officer407.44kN/A1966
Dr. Steven J. O'Day M.D., Ph.D.Chief Medical Officer970.98kN/A1961
Craig WinterChief Information OfficerN/AN/AN/A
Mr. Zack ArmenHead of Investor RelationsN/AN/AN/A
Ms. Tracy Mazza ClementeChief People OfficerN/AN/AN/A
Mr. Alfred DadsonChief Manufacturing OfficerN/AN/AN/A
Mr. Eric HumesChief Quality OfficerN/AN/AN/A
Dr. Todd Jude Yancey M.D.Member of Advisory Board & Chief Strategic AdvisorN/AN/AN/A
Dr. Robin G. Taylor M.B.A., Ph.D.Chief Commercial OfficerN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Corporate governance

Agenus Inc.’s ISS governance QualityScore as of 1 June 2024 is 8. The pillar scores are Audit: 4; Board: 9; Shareholder rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.